REDUCE-IT, biomarkers, and confirmation bias: are we missing the forest for the trees?
Open Access
- 17 May 2023
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 31 (15) , e113-e114
Abstract
Samuel C R Sherratt; REDUCE-IT, Biomarkers, and Confirmation Bias: Are We Missing the Forest for the Trees?, European Journal of Preventive Cardiology, , zwad16Keywords
This publication has 13 references indexed in Scilit:
- When Is a Placebo Not a PlaceboJAMA Cardiology, 2022
- Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker SubstudyCirculation, 2022
- Summoning STRENGTH to Question the Placebo in REDUCE-ITCirculation, 2021
- EPA and DHA containing phospholipids have contrasting effects on membrane structureJournal of Lipid Research, 2021
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular RiskJAMA, 2020
- Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studiesEuropean Heart Journal Supplements, 2020
- Effects of Icosapent Ethyl on Total Ischemic EventsJACC, 2019
- Cardiovascular Risk Reduction with Icosapent Ethyl for HypertriglyceridemiaNew England Journal of Medicine, 2019
- Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS)Atherosclerosis, 2009
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002